『Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals』のカバーアート

Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals

Biotech Business with Fexingo: Life Sciences Startups, Drug Discovery, and FDA Approvals

著者： Fexingo
無料で聴く

Lucas and Luna step into the clean, cool world of biotechnology startups, where drug discovery meets the harsh realities of FDA approvals and venture capital. Each episode takes a single biotech company—from Moderna to a tiny CRISPR spinout—and dissects its science, its business model, and the regulatory path that determines its fate. Lucas brings the numbers: clinical trial phases, patent cliffs, burn rates. Luna presses on the human stories: the researchers betting careers on a single molecule, the patients waiting for therapies that might never come. They don't celebrate hype; they ask whether the science holds up, whether the market exists, and whether the FDA will say yes. Listeners will walk away able to read a biotech 10-K, understand a Phase II readout, and spot the difference between a genuine breakthrough and a stock promotion. How do you value a company with no revenue and a 90% chance of failure? #Biotech #Lifesciences #DrugDiscovery #FDAApprovals #ClinicalTrials #Startups #VentureCapital #Pharma #Genomics #CRISPR #Therapeutics #RegulatoryScience #Patents #Investment #Business #FexingoBusiness #BusinessPodcast #Technology Keep every episode free: buymeacoffee.com/fexingo© 2026 Fexingo. All rights reserved. 経済学
エピソード
  • How Biotechs Are Using Organ Chips to Replace Animal Testing

    How Biotechs Are Using Organ Chips to Replace Animal Testing
    2026/06/08
    Episode 39 of Biotech Business with Fexingo dives into organ-on-a-chip technology—tiny devices lined with living human cells that mimic organs like lungs, livers, and hearts. Lucas and Luna explore how startups such as Emulate and TissUse are replacing animal models with these chips to accelerate drug development and cut costs. They break down the science behind the chips, highlight a case where a liver chip predicted a drug's toxicity that animal tests missed, and discuss the regulatory push from the FDA's recent mandate to reduce animal testing. The episode also touches on the market—projected to reach $5.6 billion by 2030—and the challenges of scaling manufacturing. If you're in biotech or curious about how drugs actually get approved, this is a concrete look at a technology reshaping preclinical research. #OrganOnAChip #OrgansOnChips #AnimalTestingAlternatives #DrugDiscovery #PreclinicalResearch #EmulateBio #TissUse #FDA #FDAModernizationAct #BiotechStartups #LifeSciences #Microfluidics #LiverChip #LungChip #HeartChip #Business #FexingoBusiness #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    8 分
  • How Biotech Startups Use CRISPR Screens to Find Drug Targets

    How Biotech Startups Use CRISPR Screens to Find Drug Targets
    2026/06/08
    Episode 38 of Biotech Business with Fexingo dives into how biotech startups are using CRISPR screens to systematically identify drug targets. Lucas and Luna break down the technology behind pooled CRISPR knockout screens, explain how they differ from traditional target discovery, and walk through a real example: how a startup called Maze Therapeutics used CRISPR screens to uncover a novel target for kidney disease. They also discuss the challenges of off-target effects and the shift toward in vivo screens. The episode ends with a brief, low-key note on listener support at buy me a coffee dot com slash fexingo. Perfect for anyone curious about how genomics is accelerating the first step of drug development. #CRISPR #DrugDiscovery #TargetIdentification #BiotechStartup #Genomics #MazeTherapeutics #PooledScreens #InVivoCRISPR #GeneEditing #KidneyDisease #Ganovo #BiotechBusiness #BusinessAndTechnology #FexingoBusiness #BusinessPodcast #DrugDevelopment #FunctionalGenomics #Biotech Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    12 分
  • How Biotechs Are Using Cell Painting to Profile Drugs

    How Biotechs Are Using Cell Painting to Profile Drugs
    2026/06/07
    Episode 37 of Biotech Business with Fexingo dives into cell painting — a high-content imaging technique that biotech startups are using to profile drug mechanisms, predict toxicity, and accelerate hit-to-lead decisions. Lucas explains how automated microscopy and machine learning turn thousands of cellular images into a 'morphological fingerprint' for each compound. Luna asks about scalability and how startups compete with big pharma's legacy assays. The episode walks through a concrete example: Recursion Pharmaceuticals, which uses cell painting at industrial scale, and how a new startup called Syzgy Bio is applying the method to phenotypic screens for rare diseases. Lucas closes with a forward-looking question about whether cell painting could replace traditional target-based screens. #CellPainting #DrugDiscovery #BiotechStartups #HighContentImaging #MorphologicalProfiling #PhenotypicScreen #MachineLearning #RecursionPharmaceuticals #SyzgyBio #HitToLead #DrugToxicity #LifeSciences #LabAutomation #Business #Technology #FexingoBusiness #BiotechPodcast #BusinessPodcast Keep every episode free: buymeacoffee.com/fexingo
    続きを読む 一部表示
    13 分
adbl_web_anon_alc_button_suppression_t1
まだレビューはありません